John Nemunaitis

Gradalis (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

92h-index35.6kcitations809works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(152), Cancer Research and Treatments(140), CAR-T cell therapy research(126), Immunotherapy and Immune Responses(121), Cancer Immunotherapy and Biomarkers(116)

Publications803 total

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden–High Ovarian Cancer
JCO Precision Oncology·2026Open Access
supplementary table 1 from Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
2025Open Access
Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study
Blood·2025Open Access
1029eTiP A phase I/II open-label study of NDI-219216, a WRN inhibitor, in patients with advanced solid tumors with or without microsatellite instability /deficient mismatch repair
Annals of Oncology·2025Open Access
Molecular residual disease (MRD) in solid tumors.
Journal of Clinical Oncology·2025
Impact of large language models on trial-to-patient matching efficiency.
Journal of Clinical Oncology·2025
Clinical characterization and therapeutic targeting of fusion genes in oncology
Future Oncology·2025· 1 citedOpen Access
Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product
Scientific Reports·2025· 2 citedOpen Access
Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer
Gynecologic Oncology·2024· 1 cited
Repair-assisted damage detection as a potential predictive biomarker for immunotherapy response in ovarian cancer
Gynecologic Oncology·2024
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy
Future Oncology·2024· 5 citedOpen Access
3D engineered scaffold for large-scale Vigil immunotherapy production
Scientific Reports·2024Open Access
Regulatory role of CD39 and CD73 in tumor immunity
Future Oncology·2024· 22 citedOpen Access
Data from Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
2024Open Access
supplementary table 1 from Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
2024Open Access
supplementary table 1 from Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
2024Open Access
Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer
International Journal of Molecular Sciences·2024· 7 citedOpen Access
Smart exosomes enhance PDAC targeted therapy
Journal of Controlled Release·2024· 45 citedOpen Access
Repair Assisted Damage Detection (Radd) as a Predictive Biomarker for Immunotherapy Response in Ovarian Cancer
SSRN Electronic Journal·2024Open Access
Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
Cancers·2023· 8 citedOpen Access
page 1 of 41Next →

Frequent Co-authors

Neil Senzer(13), Phillip B. Maples(6), Casey Cunningham(6), Fadlo R. Khuri(5), Kristen Hege(5), James C. Arseneau(4), Britta Randlev(4), David H. Kirn(4), James A. Merritt(4), Jack W. Singer(4), David M. Jablons(3), Ian Ganly(3), L. Romel(3), Waun Ki Hong(3), Eric J. Small(3), Donald D. Rao(3), CD Buckner(3), Joseph A. Kuhn(3), Beena O. Pappen(3), James M. Burke(3)